welcome
Investor's Business Daily

Investor's Business Daily

Health

Health

Shares of Hims & Hers plunge after bullish outlook on semaglutide

Investor's Business Daily
Summary
Nutrition label

67% Informative

Compounding pharmacy Hims & Hers stock plunges 24% in morning trades.

The company plans to skirt the FDA 's decision by selling doses of semaglutide that Novo Nordisk doesn't sell.

Hims expects $725 million in sales from weight-loss drugs this year .

The outlook includes personalized versions of Novo 's popular diabetes drug Ozempic.

VR Score

62

Informative language

64

Neutral language

3

Article tone

formal

Language

English

Language complexity

39

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links